Research
Hormonal
Metformin is the preferred initial oral hypoglycemic monotherapy for type 2 diabetes due to its efficacy, safety, and low risk of hypoglycemia and weight gain.
Start with metformin as your first medication if lifestyle changes alone aren't enough. It is the standard because it works well, is safe long-term, and rarely causes low blood sugar or weight gain. If your blood sugar isn't controlled, your doctor will add another medication.
GoodSupportsHIGH confidence
In general, the use of metformin as the first treatment for oral hypoglycemic monotherapy is recommended because of its excellent blood glucose-lowering effect, relatively low side effects, long-term proven safety, low risk of hypoglycemia, and low weight gain.
Why this rating
Based on a systematic review of multiple guidelines and cohort studies.
Source
Monotherapy in patients with type 2 diabetes mellitus
Sang Youl Rhee et al. · The Korean Journal of Internal Medicine · 2017
DOI 10.3904/kjim.2017.312
clinical_guidelineCited 8×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →